$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

$atos Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000114420414018247 Filed on March 27, 2014

Income Statement

Concept	2014 Q1	2012 Q4	2012
Revenue	$24.12K	$100.0K	$481.8K
YoY Change	-86.79%
Cost Of Revenue	$0.00	$10.00K	$35.75K
YoY Change	-100.0%	0.0%	257.45%
Gross Profit	$24.12K	$90.00K	$416.2K
YoY Change	-79.24%
Gross Profit Margin	100.0%	90.0%	86.38%
Selling, General & Admin	$2.013M	$1.330M	$3.511M
YoY Change	9.53%	23.15%	5.44%
% of Gross Profit	8342.51%	1477.78%	843.61%
Research & Development	$422.5K	$470.0K	$1.974M
YoY Change	91.88%
% of Gross Profit	1751.38%	522.22%	474.28%
Depreciation & Amortization	$125.1K	$100.0K	$130.6K
YoY Change	26.43%	900.0%	552.76%
% of Gross Profit	518.56%	111.11%	31.37%
Operating Expenses	$2.435M	$1.790M	$5.485M
YoY Change	18.34%	67.29%	64.72%
Operating Profit	-$2.411M	-$1.700M	-$5.069M
YoY Change	24.18%	58.88%	52.22%
Interest Expense	$749.00	$0.00	$12.04K
YoY Change	10600.0%	-100.0%	-220.4%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.412M	-$1.710M	-$5.080M
YoY Change	24.21%	44.92%	47.67%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.412M	-$1.710M	-$5.080M
YoY Change	24.21%	44.92%	47.57%
Net Earnings / Revenue	-9996.4%	-1710.0%	-1054.26%
Basic Earnings Per Share
Diluted Earnings Per Share	-$17.21M	-$19.00M	-$72.57M
COMMON SHARES
Basic Shares Outstanding	24.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2012 Q4	2012
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.60M	$1.700M	$1.730M
YoY Change	1085.71%	-10.53%	-9.42%
Cash & Equivalents	$16.59M	$1.725M	$1.730M
Short-Term Investments
Other Short-Term Assets	$1.000M	$100.0K	$120.0K
YoY Change	-60.0%	-90.0%	-88.35%
Inventory	$0.00	$0.00
Prepaid Expenses	$1.018M	$122.6K
Receivables	$91.42K	$141.7K	$140.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.70M	$1.989M	$1.990M
YoY Change	321.43%	-31.4%	-32.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$129.9K	$160.0K	$160.0K
YoY Change	-35.03%	59.97%	100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.553M	$4.677M	$40.00K
YoY Change			300.0%
Total Long-Term Assets	$4.683M	$4.837M	$4.840M
YoY Change	-0.36%	2318.32%	3933.33%
TOTAL ASSETS
Total Short-Term Assets	$17.70M	$1.989M	$1.990M
Total Long-Term Assets	$4.683M	$4.837M	$4.840M
Total Assets	$22.38M	$6.826M	$6.830M
YoY Change	151.5%	120.2%	122.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$0.00	$68.22K	$70.00K
YoY Change		-31.78%	16.67%
Accrued Expenses	$900.0K	$1.582M	$1.550M
YoY Change	-52.63%	295.6%	252.27%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.082M	$1.651M	$1.650M
YoY Change	-43.05%	10.04%	9.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.082M	$1.651M	$1.650M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.100M	$1.700M	$1.650M
YoY Change	-42.11%	13.33%	9.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$22.93M	-$9.732M
YoY Change
Common Stock	$24.43K	$12.92K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.30M	$5.176M	$5.180M
YoY Change
Total Liabilities & Shareholders Equity	$22.38M	$6.826M	$6.830M
YoY Change	151.5%	120.2%	122.48%

Cashflow Statement

Concept	2014 Q1	2012 Q4	2012
OPERATING ACTIVITIES
Net Income	-$2.412M	-$1.710M	-$5.080M
YoY Change	24.21%	44.92%	47.57%
Depreciation, Depletion And Amortization	$125.1K	$100.0K	$130.6K
YoY Change	26.43%	900.0%	552.76%
Cash From Operating Activities	-$2.600M	-$1.930M	-$3.900M
YoY Change	95.49%	85.58%	11.75%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	-$130.0K	-$130.0K
YoY Change	900.0%	160.0%	-7.14%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$100.0K	-$130.0K	-$130.0K
YoY Change	900.0%	160.0%	-7.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	12.96M	3.370M	3.850M
YoY Change	1196.0%		-30.38%
NET CHANGE
Cash From Operating Activities	-2.600M	-1.930M	-3.900M
Cash From Investing Activities	-100.0K	-130.0K	-130.0K
Cash From Financing Activities	12.96M	3.370M	3.850M
Net Change In Cash	10.26M	1.310M	-180.0K
YoY Change	-3117.65%	-220.18%	-109.47%
FREE CASH FLOW
Cash From Operating Activities	-$2.600M	-$1.930M	-$3.900M
Capital Expenditures	-$100.0K	-$130.0K	-$130.0K
Free Cash Flow	-$2.500M	-$1.800M	-$3.770M
YoY Change	89.39%	81.82%	12.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	atos	Proceeds From Repayments Of Commercial Line Of Credit ProceedsFromRepaymentsOfCommercialLineOfCredit	0	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3848922	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	13936823	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	23759148	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-185624	USD
CY2013Q4	us-gaap	Assets Assets	12009047	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9634	USD
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	48157	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	18574	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	7413821	USD
CY2013Q4	atos	Furniture And Equipment Net FurnitureAndEquipmentNet	163147	USD
CY2013Q4	us-gaap	Security Deposit SecurityDeposit	36446	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4395633	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4432079	USD
CY2013Q4	atos	Accrued Expenses Current AccruedExpensesCurrent	637986	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	476477	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	10601651	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12009047	USD
CY2013Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	211493	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31099691	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20516614	USD
CY2012Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	189132	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Use of Estimates:</font></strong></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.</font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	400000	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	354860	USD
CY2012Q4	atos	Prepaid Stock Purchase Agreement Service Fee PrepaidStockPurchaseAgreementServiceFee	0	USD
CY2013Q4	atos	Prepaid Stock Purchase Agreement Service Fee PrepaidStockPurchaseAgreementServiceFee	651961	USD
CY2012Q4	us-gaap	Prepaid Insurance PrepaidInsurance	62551	USD
CY2013Q4	us-gaap	Prepaid Insurance PrepaidInsurance	112517	USD
CY2012Q4	atos	Prepaid Maintenance And Support Service Fee PrepaidMaintenanceAndSupportServiceFee	0	USD
CY2013Q4	atos	Prepaid Maintenance And Support Service Fee PrepaidMaintenanceAndSupportServiceFee	131204	USD
CY2012Q4	us-gaap	Prepaid Taxes PrepaidTaxes	40082	USD
CY2013Q4	us-gaap	Prepaid Taxes PrepaidTaxes	0	USD
CY2012Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	97383	USD
CY2013Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	326824	USD
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	93664	USD
CY2013Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	93665	USD
CY2012Q4	atos	Capitalized New Product Development Costs CapitalizedNewProductDevelopmentCosts	0	USD
CY2013Q4	atos	Capitalized New Product Development Costs CapitalizedNewProductDevelopmentCosts	15000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31080	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	114050	USD
CY2012	us-gaap	Depreciation Depreciation	25082	USD
CY2013	us-gaap	Depreciation Depreciation	82970	USD
CY2012Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	4704853	USD
CY2013Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	4794853	USD
CY2012Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	50466	USD
CY2013Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	105839	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	115095	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	505059	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	400784	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	392212	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	384951	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	373990	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	373990	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2469706	USD
CY2013Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	408362	USD
CY2012Q1	atos	Accrued Payroll Liabilities AccruedPayrollLiabilities	0	USD
CY2013Q4	atos	Accrued Payroll Liabilities AccruedPayrollLiabilities	48232	USD
CY2012Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	18865	USD
CY2013Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	19883	USD
CY2012	atos	Diagnostic Testing Service DiagnosticTestingService	475402	USD
CY2013	atos	Diagnostic Testing Service DiagnosticTestingService	409118	USD
	atos	Diagnostic Testing Service DiagnosticTestingService	884520	USD
CY2012	atos	Product Sales ProductSales	6440	USD
CY2013	atos	Product Sales ProductSales	223440	USD
	atos	Product Sales ProductSales	231380	USD
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	481842	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	632558	USD
CY2012	us-gaap	Cost Of Services CostOfServices	35745	USD
CY2013	us-gaap	Cost Of Services CostOfServices	105764	USD
	us-gaap	Cost Of Services CostOfServices	141509	USD
CY2012	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	239755	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	244919	USD
CY2012	us-gaap	Cost Of Revenue CostOfRevenue	35745	USD
CY2013	us-gaap	Cost Of Revenue CostOfRevenue	345519	USD
	us-gaap	Cost Of Revenue CostOfRevenue	386428	USD
CY2012	atos	Loss On Reduction Of Inventory To Lower Of Cost Or Market LossOnReductionOfInventoryToLowerOfCostOrMarket	29884	USD
CY2013	atos	Loss On Reduction Of Inventory To Lower Of Cost Or Market LossOnReductionOfInventoryToLowerOfCostOrMarket	149946	USD
	atos	Loss On Reduction Of Inventory To Lower Of Cost Or Market LossOnReductionOfInventoryToLowerOfCostOrMarket	271856	USD
CY2012	us-gaap	Gross Profit GrossProfit	416213	USD
CY2013	us-gaap	Gross Profit GrossProfit	137093	USD
	us-gaap	Gross Profit GrossProfit	457616	USD
CY2012	us-gaap	Selling Expense SellingExpense	466821	USD
CY2013	us-gaap	Selling Expense SellingExpense	1257791	USD
	us-gaap	Selling Expense SellingExpense	1897667	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1974013	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1105110	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4662496	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3044409	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3656782	USD
CY2012	us-gaap	Profit Loss ProfitLoss	-5079851	USD
CY2013	us-gaap	Profit Loss ProfitLoss	-10784708	USD
	us-gaap	Profit Loss ProfitLoss	-20516614	USD
CY2012	atos	Common Shares Issued For Services CommonSharesIssuedForServices	0	USD
CY2013	atos	Common Shares Issued For Services CommonSharesIssuedForServices	178280	USD
	atos	Common Shares Issued For Services CommonSharesIssuedForServices	249280	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8558835	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14381171	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	5485243	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	10921736	USD
CY2013Q4	atos	Total Shares Authorized TotalSharesAuthorized	85000000	shares
	us-gaap	Operating Expenses OperatingExpenses	20941334	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-5069030	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-10784643	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20483718	USD
CY2012	us-gaap	Investment Income Interest InvestmentIncomeInterest	1219	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	295	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6883	USD
CY2012	us-gaap	Interest Expense InterestExpense	12040	USD
CY2013	us-gaap	Interest Expense InterestExpense	360	USD
	us-gaap	Interest Expense InterestExpense	39531	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5079851	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10784708	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-20516366	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	248	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-5079851	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-10784708	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20516614	USD
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.14
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12452929	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15484414	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9595967	shares
CY2010Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-2.26332
	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	862500	shares
CY2013Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2012Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1475197	USD
CY2013Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	6092161	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	386252	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	355758	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	330390	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1072400	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1052137	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1507584	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1625	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	269831	shares
CY2013	atos	Stock Issued During Period Shares Stock Options Exercised1 StockIssuedDuringPeriodSharesStockOptionsExercised1	5546	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2282719	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1063612	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2125932	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.79
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.86
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.00
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.40
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.79
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.43
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.49
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.43
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M20D
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M2D
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y9M14D
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	130552	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	472934	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	619109	USD
CY2012	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0	USD
CY2013	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	211493	USD
	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	211493	USD
CY2012	atos	Bad Debt Expense BadDebtExpense	0	USD
CY2013	atos	Bad Debt Expense BadDebtExpense	354861	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1150416	USD
	atos	Bad Debt Expense BadDebtExpense	354861	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	140441	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	121812	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	1443760	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1736024	USD
CY2012	atos	Loss On Reduction Of Inventory LossOnReductionOfInventory	29884	USD
CY2013	atos	Loss On Reduction Of Inventory LossOnReductionOfInventory	149946	USD
	atos	Loss On Reduction Of Inventory LossOnReductionOfInventory	271856	USD
CY2012	atos	Loan Initiation Fee Accrued For Notes Payable LoanInitiationFeeAccruedForNotesPayable	0	USD
CY2013	atos	Loan Initiation Fee Accrued For Notes Payable LoanInitiationFeeAccruedForNotesPayable	0	USD
	atos	Loan Initiation Fee Accrued For Notes Payable LoanInitiationFeeAccruedForNotesPayable	2000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	352267	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	493932	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	29884	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	149946	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	271856	USD
CY2012	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	91449	USD
CY2013	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	57994	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	180627	USD
CY2012	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-29089	USD
CY2013	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-36447	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3451	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-58583	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9634	USD
CY2012	atos	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	-33219	USD
CY2013	atos	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	268480	USD
	atos	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	268480	USD
CY2012	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
CY2013	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	48157	USD
	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	48157	USD
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1198860	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-704372	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	923008	USD
CY2012	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	19410	USD
CY2013	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-8377	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-8377	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3899964	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8830044	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16655659	USD
CY2012	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	104582	USD
CY2013	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	244442	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	435489	USD
CY2012	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	30000	USD
CY2013	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	245373	USD
	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	325839	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-134582	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-489815	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4616964	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6342161	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1910821	USD
CY2009Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-761328	USD
CY2012	atos	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	3854000	USD
CY2013	atos	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	13936823	USD
	atos	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	23761148	USD
CY2012	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-1000000	USD
CY2013	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	USD
CY2012	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-5078	USD
CY2013	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-2000	USD
CY2012	atos	Proceeds From Repayments Of Commercial Line Of Credit ProceedsFromRepaymentsOfCommercialLineOfCredit	1000000	USD
CY2013	atos	Proceeds From Repayments Of Commercial Line Of Credit ProceedsFromRepaymentsOfCommercialLineOfCredit	0	USD
CY2012	us-gaap	Interest Paid InterestPaid	14715	USD
CY2013	us-gaap	Interest Paid InterestPaid	360	USD
	us-gaap	Interest Paid InterestPaid	33067	USD
CY2012	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2013	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	248	USD
CY2012	atos	Common Stock And Warrants Issued For Assets Purchase CommonStockAndWarrantsIssuedForAssetsPurchase	4674853	USD
CY2013	atos	Common Stock And Warrants Issued For Assets Purchase CommonStockAndWarrantsIssuedForAssetsPurchase	0	USD
	atos	Common Stock And Warrants Issued For Assets Purchase CommonStockAndWarrantsIssuedForAssetsPurchase	4674853	USD
CY2012	atos	Options Issued For Previously Accrued Director Compensation OptionsIssuedForPreviouslyAccruedDirectorCompensation	45000	USD
CY2013	atos	Options Issued For Previously Accrued Director Compensation OptionsIssuedForPreviouslyAccruedDirectorCompensation	0	USD
	atos	Options Issued For Previously Accrued Director Compensation OptionsIssuedForPreviouslyAccruedDirectorCompensation	45000	USD
CY2012	atos	Commitment Shares Issued For Shares Distributed For Capital Contribution CommitmentSharesIssuedForSharesDistributedForCapitalContribution	0	USD
CY2013	atos	Commitment Shares Issued For Shares Distributed For Capital Contribution CommitmentSharesIssuedForSharesDistributedForCapitalContribution	3137500	USD
	atos	Commitment Shares Issued For Shares Distributed For Capital Contribution CommitmentSharesIssuedForSharesDistributedForCapitalContribution	3137500	USD
CY2012	atos	Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution	0	USD
CY2013	atos	Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution	2485540	USD
	atos	Amortization Of Commitment Shares Issued For Shares Distributed For Capital Contribution AmortizationOfCommitmentSharesIssuedForSharesDistributedForCapitalContribution	2485540	USD
CY2012Q3	us-gaap	Share Price SharePrice	5.00
	atos	Warrants Issued During Period Acquisitions WarrantsIssuedDuringPeriodAcquisitions	325000	shares
	atos	Warrants Exercise Price WarrantsExercisePrice	5.00
	atos	Warrant Terms WarrantTerms	P5Y
	atos	Warrant Price WarrantPrice	2.3457
CY2013	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">NOTE 1: NATURE OF OPERATIONS</font></b></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Company’s operations began in December 2008 with the negotiations for the acquisition of the Mammary Aspirate Specimen Cytology Test System, or the MASCT System, patent rights and assignments and the FDA clearance for marketing, which acquisition was completed in January 2009. Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market the MASCT System, which is a medical device that collects specimens of nipple aspirate fluid (NAF). The Company’s fiscal year ends on December 31st.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">In December 2011, the Company established the National Reference Laboratory for Breast Health, Inc., or NRLBH, as a wholly-owned subsidiary. NRLBH is the Company’s CLIA-certified laboratory which performs <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">our NAF cytology test</font> on NAF specimens including those collected with the MASCT System. The current version of the MASCT System is called the ForeCYTE Breast Aspirator. The NRLBH <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">is developing other tests such as</font> the ArgusCYTE test on blood sample from breast cancer survivors to detect circulating tumor cells.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">In September 2012, the Company acquired the assets of Acueity Healthcare, Inc. (“Acueity”). The purchased assets included of the intellectual property rights related to the Viaduct Miniscope and accessories, the Manoa Breast Biopsy system, the Excisor Bioptome, the Acueity Medical Light Source, the Viaduct Microendoscope and accessories, and cash in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400,000</font>. The microendoscopes are less than 0.9 mm outside diameter and can be inserted into a milk duct. This permits a physician to pass a microendoscope into the milk duct system of the breast and view the duct system via fiberoptic video images. Abnormalities that are visualized can then be biopsied from inside the duct with the biopsy tools that are inserted adjacent to the microendoscope. The patents relate to intraductal diagnostic and therapeutic devices and methods of use. The Company did not, however, acquire an inventory of these diagnostic tools, manufacturing capabilities or any personnel to market and sell the tools. The Company cannot provide any assurance that it will be successful commercializing these tools.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Development Stage Risk</font></u></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">From April 30, 2009 (inception) through December 31, 2013, the Company earned $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,115,900</font> in revenue from the sale of its MASCT System and laboratory services. The Company’s activities have been accounted for as those of a “Development Stage Enterprise” as set forth in Accounting Standards Codification (“ASC”) 915 “Development Stage Entities”, which was previously Statement of Financial Accounting Standards No. 7 (“SFAS 7”). Among the disclosures required by ASC 915 are that the Company’s financial statements be identified as those of a development stage company, and that the statements of operations, stockholders’ equity and cash flows disclose activity since the date of the Company’s inception.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plan will be successfully executed. The Company’s ability to execute its business plan will depend on its ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Further, the Company cannot give any assurance that it will generate substantial revenue or that its business operations will prove to be profitable.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	31683	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	-851851	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	1559721	USD
CY2009Q2	us-gaap	Stockholders Equity StockholdersEquity	54000	USD
	atos	Stock Issued During Period Value New Issues One StockIssuedDuringPeriodValueNewIssuesOne	540	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-1086930	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-3442268	USD
	us-gaap	Net Income Loss NetIncomeLoss	-122857	USD
CY2010	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	102000	USD
CY2011	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	5713785	USD
CY2012	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	3454000	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	12303745	USD
CY2010	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	71000	USD
CY2013	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	180252	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	30396	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	140056	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	166812	USD
CY2013	dei	Trading Symbol TradingSymbol	ATOS
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1443760	USD
CY2012	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	4312500	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	762353	USD
CY2012	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	158292	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	158292	USD
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24428568	shares
CY2013	dei	Entity Registrant Name EntityRegistrantName	ATOSSA GENETICS INC
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001488039
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q2	dei	Entity Public Float EntityPublicFloat	54125110	USD
	atos	Stock Issued During Period Value New Issues Two StockIssuedDuringPeriodValueNewIssuesTwo	100000	USD
CY2012Q4	us-gaap	Deposit Assets DepositAssets	0	USD
CY2013Q4	us-gaap	Deposit Assets DepositAssets	36906	USD
CY2012Q4	atos	Allowance For Loss On Impairment Of Assets AllowanceForLossOnImpairmentOfAssets	0	USD
CY2013Q4	atos	Allowance For Loss On Impairment Of Assets AllowanceForLossOnImpairmentOfAssets	158292	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1443760	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	140056	USD
CY2013	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	24510	shares
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	50000	USD
CY2013	atos	Stock Issued During Period Value For Capital Raising Fees StockIssuedDuringPeriodValueForCapitalRaisingFees	651961	USD
CY2013	atos	Stock Issued During Period Value For Warrant StockIssuedDuringPeriodValueForWarrant	1621182	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9924	USD
CY2011Q4	atos	Fair Value Of Common Stock Decreased FairValueOfCommonStockDecreased	0.906
CY2010Q4	atos	Fair Value Of Common Stock Decreased FairValueOfCommonStockDecreased	2.756
CY2012Q4	atos	Prepaid Media Relations Service Fee PrepaidMediaRelationsServiceFee	20000	USD
CY2013Q4	atos	Prepaid Media Relations Service Fee PrepaidMediaRelationsServiceFee	0	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2013Q4	atos	Recall Expenses Actual RecallExpensesActual	223750	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	0	USD

Files In Submission

Name	View Source	Status
0001144204-14-018247-index-headers.html	Edgar Link	pending
0001144204-14-018247-index.html	Edgar Link	pending
0001144204-14-018247.txt	Edgar Link	pending
0001144204-14-018247-xbrl.zip	Edgar Link	pending
atos-20131231.xml	Edgar Link	completed
atos-20131231.xsd	Edgar Link	pending
atos-20131231_cal.xml	Edgar Link	unprocessable
atos-20131231_def.xml	Edgar Link	unprocessable
atos-20131231_lab.xml	Edgar Link	unprocessable
atos-20131231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ft0001img-1.jpg	Edgar Link	pending
ft0001img-2.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tfooter.jpg	Edgar Link	pending
tgraph.jpg	Edgar Link	pending
v371048_10k.htm	Edgar Link	pending
v371048_ex10-32.htm	Edgar Link	pending
v371048_ex10-33.htm	Edgar Link	pending
v371048_ex10-35.htm	Edgar Link	pending
v371048_ex23-1.htm	Edgar Link	pending
v371048_ex31-1.htm	Edgar Link	pending
v371048_ex31-2.htm	Edgar Link	pending
v371048_ex32-1.htm	Edgar Link	pending
v371048_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

2014 Q1 Form 10-K Financial Statement

#000114420414018247 Filed on March 27, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS ATOSSA THERAPEUTICS, INC. Stock $atos

2014 Q1 Form 10-K Financial Statement

#000114420414018247 Filed on March 27, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos